MSD的keytruda在非小细胞肺癌的另一项临床试验中大获成功

2018-04-10 MedSci MedSci原创

默沙东公司(MSD)的Keytruda在一线治疗中无论患者PD-L1的表达水平如何,均能显着提高肺癌患者的总生存期。这一结果显着增加了Keytruda的临床治疗范围。

默沙东公司(MSD)的Keytruda在一线治疗中无论患者PD-L1的表达水平如何,均能显着提高肺癌患者的总生存期。这一结果显着增加了Keytruda的临床治疗范围。

三期临床试验KEYNOTE-042评估了PD-1抗体治疗局部晚期或转移性非小细胞肺癌(NSCLC)患者的效果。中期分析显示,在PD-L1肿瘤比例评分(TPS)≥1%的患者中,用Keytruda(pembrolizumab)治疗的患者的总体生存期明显长于铂类化疗。

Keytruda作为唯一被批准NSCLC一线单药治疗的PD-1抗体,尽管最初批准是用于TPS>50%的患者,但是现在该药物的适应症已经扩大任何PD-L1表达水平的患者。

香港中文大学临床肿瘤学教授Tony Mok博士说:"总体生存期的改善是晚期肺癌治疗的最终目标。KEYNOTE-042是首个进入III期临床研究中的单药治疗的免疫药物,展现出对PD-L1阳性率≥1%非小细胞肺癌患者的一线治疗效果。"

该试验将继续评估次要终点无进展生存期(PFS),试验结果将提交给全球监管机构。

原始出处:

http://www.pharmatimes.com/news/msds_keytruda_bags_another_trial_success_in_nsclc_1231055

此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-13 大爰

    学习并分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 hanmeijinxiu

    不错不错.新知识.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 zhangj7112
  6. [GetPortalCommentsPageByObjectIdResponse(id=2059696, encodeId=ad2f2059696dd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Oct 17 21:41:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305497, encodeId=aa8a30549e2d, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:33:18 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305101, encodeId=25673051011e, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Apr 12 13:28:10 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305077, encodeId=b9f93050e7bb, content=不错不错.新知识.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu Apr 12 10:45:02 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Thu Apr 12 06:41:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304965, encodeId=fe8e304965e2, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Apr 12 05:58:32 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

Nature:PD-1抗体为何对有些患者无效?肿瘤大小在“作祟”!

扩大癌症免疫疗法的获益人群是很多科学家团队正在努力攻克的难题。解决这一问题的前提是,弄清楚为何包括PD-1抗体在内的这类疗法不能对一些患者“奏效”。本周发表在《自然》杂志上的一项新成果发现,这种“不奏效”与患者治疗前的肿瘤大小有关。

全球针对肝癌的PD-1抗体获FDA批准,奋起直追,国产PD-1抗体顺利进入三期临床

作为一项严重的全球性健康问题,肝癌(HCC)是癌症相关死亡率的第二大原因,肝癌(HCC)难治已是众所周知!全球每年约有782,000例新发病例,造成的死亡人数约为746,000例。而中国约占全球新发HCC病例和HCC相关死亡人数的50%。也就是说,全世界几乎一半的肝癌患者都在中国。此外,国内大部分的肝癌患者,发现就是晚期,没有了手术的机会。但就目前来看,治疗晚期肝癌的药物并不多,对于这类患者来说,

EUR J CANCER:Nivolumab相关的免疫不良事件:恶心和呕吐

大红大紫的免疫治疗,包括CAR-T疗法及程序性细胞死亡蛋白1(PD-1)抗体疗法,重磅药物PD-1/PD-L1抗体已经累计被批准了11个肿瘤适应症,包括黑色素瘤、非小细胞肺癌、肾细胞癌、霍奇金淋巴瘤、头颈癌、膀胱癌、结直肠癌、胃癌、肝癌、默克尔细胞癌以及错配修复缺陷(dMMR)的实体瘤。PD-1抗体Nivolumab已经被用于转移性黑色素瘤及鳞状非小细胞肺癌的治疗。尽管,相比于具有细胞毒性的T淋巴

JCI:Dinaciclib诱导免疫原性细胞死亡并增强PD-1抗体介导的肿瘤抑制

免疫检查点(PD-1)抑制剂已经在治疗癌症的临床上中显示出了巨大的成功,然而,大多数肿瘤对PD-1抗体的单一疗法具有抗性。许多正在进行的联合治疗研究揭示出PD-1抗体与其他治疗药物的相互补充可能产生更好的效果。

JCI:IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应

JCI:IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应 Pembrolizumab已经被广泛用于晚期黑色素瘤的治疗,相比于化疗或伊匹单抗,pembrolizumab能够显著提高晚期黑色素瘤患者的总生存期。 靶向程序化死亡蛋白(PD-1)从而实现肿瘤细胞

EUR J CANCER:转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应

皮肤顶浆分泌腺癌(Cutaneous apocrine adenocarcinoma)是一种罕见的汗腺癌,其发病部位多处于上躯干和头/颈部区域。对于该疾病,预测患者生存期的最重要的评判标准即为阳性淋巴结状态。而对于转移性皮肤顶浆分泌腺癌患者,目前尚无有效的治疗方法,因此患者5年总生存率低于10%。